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ABSTRACT Sabeluzole was described to have antiischemic, antiepileptic, and
cognitive-enhancing properties, and is currently under development for Alzheimer’s
disease. Recently, it was reported that repeated treatments with sabeluzole protect
cultured rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity.
We evaluated the possibility that sabeluzole elicits neuroprotection by acting, either
directly or indirectly, on tau proteins. We found that repeated treatments during
development of primary cultures of cerebellar granule cells with nanomolar concentra-
tions of sabeluzole resulted in mature cells that were resistant to the excitotoxicity
induced by glutamate. Also, sabeluzole treatment specifically prevented the glutamate-
induced increase of tau expression without modifying the basal pattern of expression of
tau proteins, as shown by measurement of mRNA and protein levels. In human
neuroblastoma cell line SH-SY5Y, differentiated by treatment with retinoic acid,
doxorubicin increased tau immunoreactivity, and later induced cell death. Both effects
were prevented by sabeluzole. Our data indicate that increased tau expression is a
common response to different types of cells to neurotoxic agents, and that sabeluzole-
induced neuroprotection is functionally associated with the prevention of the injury-
mediated increase of tau expression. Synapse 26:95–103, 1997. r 1997 Wiley-Liss, Inc.
INTRODUCTION
Sabeluzole is an experimental drug originally devel-
oped for its antiischemic, antiepileptic (Wauquier et al.,
1986), and cognitive-enhancing properties (Clinke and
Sahgal, 1986), and it is currently under development
for Alzheimer’s disease. Recently, it was reported that
repeated treatments with sabeluzole protect cultured
rat hippocampal neurons against NMDA- and gluta-
mate-induced neurotoxicity (Pauwels et al., 1990). How-
ever, the site(s) as well as the mechanism(s) of action of
sabeluzole responsible for its neuroprotective proper-
ties are up to now largely unknown.
We tested the possibility that sabeluzole may elicit
neuroprotection by acting, either directly or indirectly,
on tau expression. Tau proteins are cytoskeleton-
associated, neural proteins promoting microtubule as-
sembly and neurite polarization (Caceres and Kosik,
1990; Dubrin and Kirschner, 1986). The interest in tau
proteins has recently been increased by the finding that
tau proteins are the major component of neurofibrillary
tangles, one of the hallmarks of theAlzheimer’s disease
brain (Braak et al., 1986). We previously found that
inhibition of tau expression by tau oligonucleotide
antisense treatment in primary cultures of cerebellar
granule cells reduced neural vulnerability to glutamate-
induced neurotoxicity (Pizzi et al., 1995a). Increased
tau expression may thus be considered one of the
crucial steps in the chain of intracellular events, in-
duced by glutamate, leading to neural death.
In this report we show that increased tau expression
is a converging effect induced by a variety of neurotoxic
agents, and that the neuroprotective properties of
sabeluzole, independent of type of experimental injury,
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Primary cultures of cerebellar granule cells were
prepared from 8-day-old Sprague-Dawley rat pups as
previously described (Levi et al., 1984). Cells were
plated onto poly-1-lysine-coated dishes and cultured in
basal Eagle’s medium containing 10% heat-inactivated
fetal calf serum, 2 mM glutamine, 50 µg/ml gentamicin,
and 25 mM KCl, at a density of 1.5 3 105 cells/cm2.
Cytosine arabinoside (100 µM) was added to the cul-
tures 18 h after seeding to prevent non-neuronal cell
proliferation. Experiments were done after culturing
the neurons for 12 days in vitro (DIV) unless otherwise
indicated. Neuroblastoma cell line SH-SY5Y was rou-
tinely cultured in 1:1 Ham’s F12 Dulbecco’s modified
Eagle’s medium with 10% fetal calf serum, 2 mM
glutamine, in 120-mm Falcon plastic petri dishes in
humidified incubators at 37°C with 5% CO2. For differ-
entation, cultures were seeded at approximately 105
cells/dish, and retinoic acid was added to give a final
concentration of 1025 µM. Medium was changed on
alternate days, and cultures were allowed to differenti-
ate for at least 3 weeks.
Neurotoxicity assay
The culture-conditioned media of cerebellar granule
cells were collected, and the cells were washed once
with Locke’s solution (154 mM NaCl, 5.6 mM KCl, 3.6
mM NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose, and 5
mMHEPES, pH 7.4) and exposed to different concentra-
tions of glutamate for 15 min. After this period, cells
were washed three times with Locke’s solution contain-
ing 1 mM MgSO4 and returned to the original culture-
conditioned media. Cells were cultured for an addi-
tional 24 h before intravital staining was performed. To
evaluate the acute effect of sabeluzole, 0.001% dimethyl
solfoxide (DMSO) or sabeluzole, prepared from a 100-
fold concentrated drug solution in 0.1% DMSO, were
added 20 min before the glutamate pulse. When the
chronic effect of sabeluzole was investigated, vehicle or
the drug, prepared as described above, was added to the
cultures on DIV 5 and DIV 8. Cell viability was
determined by fluorescein diacetate (15 µg/ml) and
propidium iodite (80 µg/ml) staining as previously
described (Jones and Senft, 1985).
Neurotoxicity experiments were also performed on
differentiated neuroblastoma SH-SY5Y cells. The acute
effects of sabeluzole were evaluated by pretreating the
cells with vehicle or the drug 20 min before cell injury,
while chronic effects were studied by adding vehicle or
sabeluzole on DIV 14 and DIV 18. On DIV 21, 10 nM
doxorubicin, an anthracycline antibiotic that induces
DNA damage (Cole et al., 1985), was added to the
medium; 24 h later, neurotoxicity was evaluated as
percentage of total lactate dehydrogenase (LDH) activ-
ity. Extracellular and intracellular LDH activity was
measured spectrophotometrically, following NADH-
oxidation at 340 nm (Bergmeyer, 1974; Pauwels et al.,
1989). Total LDH activity was defined as the sum of
intracellular and extracellular LDH activity.
Intracellular calcium concentration
measurement
Regulation of cytosolic free calcium concentration
was investigated by microfluorimetry in single cerebel-
lar granule neurons, according toMalgaroli et al. (1987)
with minor modifications (Pizzi et al., 1995a). Briefly,
cells were plated onto 100 µg/ml poly-l-lysine-coated
glass coverslips and cultured as described above. On
DIV 12, cells were loaded with the calcium-sensitive
fluorescent dye fura-2, by a 60-min incubation at 37°C
with its acetoxymethyl derivate (4 µM in Krebs-Ringer
medium containing 1.3 mg/ml bovine serum albumin,
pH 7.4), and then mounted in a 22-mm holder. Fura-2
emission was monitored using an inverted fluorescence
microscope (Nike Diaphot, Ni Ron, Japan) associated
with an intensified charge-coupled device camera (Mira-
100 TE; Applied Imaging, Gateshead, UK) which re-
corded the 510-nm fluorescence emission in neurons
excited through a narrow bandpass filter (340 and 380
nm). The background was subtracted, and the amount
of free calcium within the cell bodies was calculated
from the ratio of 340/380 nm obtained every 3–4 sec.
Calibration was according to external standards of
calcium and fura-2 (Connor, 1986). Fluorescence image
acquisition and analysis were performed using the
MIRAcal (Multiple Image Ratioing and Analysis with
Calibration) system byApplied Imaging.
Polymerase chain reaction
A polymerase chain reaction (PCR)-derived method
was used to determinate tau mRNA levels in cerebellar
granule cells (Pizzi et al., 1995b) and in the neuroblas-
toma SH-SY5Y cell line. Total mRNAwas isolated from
the cultures by the method of RNAzol (Chirgwin et al.,
1979; Chomczynski and Sacchi, 1987), extracted by
chloroform-ethanol, and reverse-transcribed with
Moloney murine leukemia virus reverse transcriptase
in the presence of [32P]dCTP, as recommended by the
manufacturer (BRL). The resulting cDNA was quanti-
tated by determining the amount of radioactivity incor-
porated into trichloroacetic acid-precipitable nucleic
acids. PCR was done with Taq polymerase (Perkin-
Elmer Cetus) in 100 µl of standard buffer containing 0.5
ng cDNA, [32P]dCTP as radioactive tracer, and 1 µM
specific primers. The following primers were used:
58-AGCCGCCTACAGACTGCCCCTGTG-38, correspond-
ing to nucleotides 693–717 and referred to as A, and 38-
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ATTTCTGCTCCATGGTCTGTCTTG-58, corresponding
to nucleotides 1124–1147 and referred to as B, of the rat
tau cDNA sequence (Kosik et al., 1989). Human tau
cDNA sequencing was performed using the following
specific primers: 58-AGCCGCCTGCAGACAGCCCCC-
GTG-38, corresponding to nucleotides 546–570 and
referred to as A8, and 38-ATCTCCGCCCCGTGGTCT-
GTCTTG-58, corresponding to nucleotides and 885–909
referred to as B8. Thirty cycles of amplification were
performed with a DNA Thermal Cycler (Perkin-Elmer
Cetus) and a step program (94°C, 30 sec; 60°C, 30 sec;
72°C, 60 sec), followed by a 15-min final extension. PCR
products were separated by electrophoresis, visualized
by ethidium bromide staining, and cut out. The radioac-
tivity incorporated into the bands was counted by
scintillation spectrometry. The data are expressed as
the ratio between the radioactivity incorporated by the
two isoforms of PCR product.
Western blot analysis
Ten million granule cells were harvested in 100 µl of
lysis buffer containing 50 mM Tris, pH 7.6, 150 mM
NaCl, 5 mM EDTA, 1 mM phenyl methyl sulphonyl
fluoride, 0.5 µg/µl leupeptin, 5 µg/µl aprotinin, and 1
µg/ml pepstatin. The suspension was sonicated for 30
sec at full power and centrifuged at 15,000g for 30 min
at 4°C. The resulting supernatant was isolated, and
protein content was determined by a conventional
method (BCA Protein Assay Kit, Pierce, Rockford, IL).
Thirty µg of total proteins were electrophoresed on 10%
sodium dodecylsulphate-polyacrylamide gel electropho-
resis, and transferred to nitrocellulose paper (Schlei-
cher and Schuell, Dassel, Germany). Filters were incu-
bated at 4°C overnight with a phosphate-independent
tau polyclonal antibody (anti-tau Sigma, 1:100) (Dubrin
et al., 1984) in 3% nonfat dried milk (Sigma, St. Louis,
USA). For immunodetection, a goat anti-rabbit alkaline
phosphatase conjugate antibody (Promega, Madison,
USA), 1:7,500 dilution, was used.
Immunocytochemistry
Tau immunoreactivity was measured 2 h after the
glutamate pulse according to a previously described
procedure (Mattson, 1990; Pizzi et al., 1995a) on the
cerebellar granule cells, and 2 h after the addition of
doxorubicin to differentiated SH-SY5Y cells. Briefly,
cultures were fixed for 30 min in 50 mM phosphate-
buffered saline (PBS) containing 4% paraformaldehyde.
Following several rinses in PBS, cells were incubated
for 20 min in Tris-buffered saline containing 0.5%
hydrogen peroxide to block endogenous peroxidase stain-
ing. Cells were then permeabilized by a 5-min exposure
to 0.2% Triton X-100 in PBS, and incubated for 24 h at
8°C with the primary antibody, an anti-tau monoclonal
antibody Alz50 (1:100). The Alz50 epitope is at the
amino terminal of tau. It comprises amino acids 2–10 of
tau, a sequence that appears to be conformationally
sensitive to hyperphosphorylation associated with Alz-
heimer’s disease tau (Goedert et al., 1991; Goedert,
1993; Lang et al., 1992). After rinses, cells were pro-
cessed using an avidin-biotin complex kit (ABC Elite
Kit, Vector Laboratories, Burlingame, USA). Enzy-
matic reaction was developed as described by Mattson
(1990). In order to verify the specificity of the cromogen
reaction, some dishes were processed identically, except
that cells were incubated with the primary antibody
solvent. In these conditions, no immunostaining was
generated.Ablind analysis of immunoreactive cells was
performed in all dishes. Aminimum of 100 neurons was
counted in at least three fields of three different culture
dishes. A semiquantitative study of immunoreactivity
was carried out using the Magiscan Image Analysis
System (Joyce-Loebl Ltd., London, UK). The General
Image Analysis Software (Genias) provided by Joyce-
Loebl as standard with Magiscan gave us access to the
image-processing and analysis functions of Magiscan.
The microdensitometry analysis was performed as pre-
viously described (Mize et al., 1988) by measuring the
following parameters in each cell body: 1) integrated
optical density (ID), i.e., the sum of optical density (OD)
for each pixel in the cell area considered; and 2) area,
i.e., the sum of pixels over the image of the cell point set.
The ratio of ID/area from each cell was processed for the
statistical analysis. The data were evaluated as gray
levels, expressed by a defined score: A 5 0–8 3 1022
OD/pixel; B 5 9–16 3 1022 OD/pixel; C 5 17–30 3 1022
OD/pixel. The statistical significance of differences be-
tween values was tested by analysis of variance. Data
are presented as mean 6 SEM of at least three experi-
ments.
RESULTS
Neuroprotective effects of sabeluzole in
cerebellar granule cells
Neurotoxicity
The effects of sabeluzole on glutamate-mediated exci-
totoxicity in primary culture of cerebellar granule cells
were evaluated using two different experimental para-
digms: after acute treatment (i.e., 20 min before the
glutamate pulse), and after repeated treatment (i.e., by
exposing the cells to the drug twice during in vitro
maturation). In the former case, 12-DIV cultures were
pretreated for 20 min with vehicle, 5 µM MK 801, a
noncompetitive antagonist on NMDA-type glutamate
receptor, or sabeluzole (50 nM and 100 nM). Then,
glutamate at a concentration of 50 µM or 100 µM was
added to the dishes, and incubation was allowed for an
additional 15 min. Cells were washed out of the gluta-
mate, and viability was tested 24 h later. While MK 801
completely prevented glutamate-induced neuronal
death, no protective effect was observed in the cultures
pretreated with sabeluzole or vehicle (Table I).
97SABELUZOLE INHIBITS CELL DEATH
The effects of repeated treatment of sabeluzole on
glutamate-induced neurotoxicity were investigated by
exposing the cells to the drug during in vitro matura-
tion, specifically at DIV 5 and DIV 8. Cells were
cultured for an additional 4 days and on DIV 12, at
which point they were fully differentiated, they were
exposed to a 15-min glutamate pulse. This experimen-
tal paradigm will be referred to as ‘‘repeated treat-
ment.’’ Figure 1 shows the results obtained by measur-
ing glutamate-induced neurotoxicity in cells repeatedly
treated with vehicle or different concentrations of sabe-
luzole, ranging from 1–100 nM. The tested drug showed
a dose-dependent neuroprotective effect. In particular,
sabeluzole at the concentration of 50 nM reduced cell
death by about 50%, in comparison to vehicle. The
neurotoxic effects of increased concentrations of gluta-
mate, ranging from 10–100 µM, were also evaluated in
cerebellar granule cells repeatedly treated with vehicle
or 50 nM sabeluzole. As shown in Figure 2, 50 µM and
100 µM glutamate reduced cell viability by 54% and
70%, respectively, in control cells. Repeated treatment
with sabeluzole prevented the neurotoxicity induced by
50 µM and 100 µM glutamate by 32% and 48%,
respectively.
Intracellular calcium concentration
The levels of intracellular Ca11 concentrations
([Ca11]i) after a glutamate pulse were measured in
cerebellar granule cells repeatedly treated with vehicle
or sabeluzole. As shown in Figure 3a, 50 µM glutamate
evoked a rapid [Ca11]i rise followed by a sustained
plateau ([Ca11]i 5 500 6 52 nM) in all control neurons
investigated (30 cells taken from two different cell
preparations). Repeated treatment of cells with 50 nM
sabeluzole, a concentration that was shown to induce
50% neuroprotection, did not alter neuron responsive-
ness to glutamate in terms of [Ca11]i rise. As shown in
Figure 3b, in 50 nM sabeluzole pretreated cells, gluta-
mate induced a rapid [Ca11]i elevation followed by a
plateau with kinetics and intensity similar to those
detected in untreated cells. Even higher concentrations
of sabeluzole (100 nM) did not reduce the calcium
response of cells to glutamate (Fig. 3c).
TABLE I. Neuroprotection against glutamate-induced toxicity
















Fig. 1. Inhibition of glutamate-induced neurodegeneration by in-
creasing concentrations of sabeluzole. Sabeluzole or vehicle were
added to neurons on DIV 5 and DIV 8. Experiments were done on DIV
12. Data (mean 6 SEM of five or six determinations) are from a
representative experiment repeated with similar results in at least
three separate preparations of neurons. Glutamate per se induced cell
death in about 80% of untreated cells. *P , 0.01 vs. the values in
vehicle-treated cells.
Fig. 2. Dose-dependent neurotoxic effects of glutamate in primary
cultures of cerebellar granule cells pretreated with vehicle (squares) or
50 nM sabeluzole (circles). Sabeluzole or vehicle was added to neurons
on DIV 5 and DIV 8. Experiments were done on DIV 12. Values
represent percentage of cell survival 24 h after the glutamate pulse.
Data (mean 6 SEM of five or six determinations) are from a represen-
tative experiment repeated with similar results in at least three
separate preparations of neurons. *P , 0.01 vs. the corresponding
glutamate concentration values in vehicle-pretreated cells.
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Tau expression
Asemiquantitative PCR-derived method was applied
to evaluate tau mRNA content in primary cultures of
cerebellar granule cells during in vitro maturation.
PCR analysis yielded two distinct cDNA bands corre-
sponding to about 360 bp and 455 bp. The longer PCR
product corresponded to that theoretically expected on
the basis of the tau sequence, while the shorter one
reflected tau mRNA species lacking one 93-bp repeat.
These two bands have been respectively referred to as
‘‘mature’’ and ‘‘fetal’’ tau mRNA isoforms. As shown in
Figure 4A, granule cells virtually entirely express the
fetal tau isoforms on DIV 1 and DIV 3, both the adult
and the fetal tau isoforms on DIV 6 and DIV 9, and
predominantly the adult tau isoforms on DIV 12. The
ratio between adult and fetal isoforms increases with
time in culture, the fetal isoform tending to decrease
and virtually disappearing by DIV 12. The PCR prod-
ucts derived from cultures repeatedly treated with 50
nM sabeluzole did not show any difference compared to
age-matched, vehicle-treated cells. Furthermore, data
obtained by calculating the amount of radioactivity
incorporated into the bands on different DIV did not
point out any difference between treated and untreated
cells (Fig. 4B).
Immunoblot analysis was used to verify whether
repeated treatment with sabeluzole could induce modi-
Fig. 3. Original recordings showing the glutamate-induced [Ca11]i
rise in cerebellar granule cells. a: Effect of 50 µM glutamate on [Ca11]i
in vehicle-pretreated neurons. b: Effect of 50 µM glutamate on [Ca11]i
in 50 nM sabeluzole-pretreated neurons. c: Effect of 50 µM glutamate
on [Ca11]i in 100 nM sabeluzole-pretreated neurons. Sabeluzole or
vehicle was added to culture medium on DIV 5 and DIV 8. Experi-
ments were done on DIV 12. Values are from representative neuron
recordings. Bars represent time of glutamate exposure.
Fig. 4. Developmental changes of tau mRNA processing during in
vitro maturation of cerebellar granule cells treated with vehicle (open
bars) or 50 nM sabeluzole (shaded bars). A: PCR products using
specific primers to amplify both the adult and fetal tau isoforms.
Numbers at top correspond to DIV. Data are from a representative
experiment. B: Semiquantitative analysis. Results are expressed as
the ratio calculated by dividing the data from the mature isoform by
the data from the fetal one. Data are cpm of [32P]dCTP incorporated
into the PCR-amplified bands, and represent the mean 6 SEM of at
least four experiments using two separate cDNA preparations from
two different sets of cell cultures.
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fication in protein levels. A representative immunoblot
is shown in Figure 5. Heat-stable extracts were ob-
tained from granule cells repeatedly treated with ve-
hicle (Fig. 5, lane 1) or 50 nM sabeluzole (Fig. 5, lane 2).
The immunostaining performed with the phosphate-
independent tau polyclonal antibody (Binder et al.,
1985) detected five sharp bands with apparent MW
ranging from 68–45 kDa. The anti-tau antibody has
been largely described for bovine and rat tissue by
Binder et al. (1985), and recognizes all of the known
electrophoretic tau isoforms on immunoblots ofmamma-
lian brain. Densitometric analysis of the immunoblot
shown in Figure 5 revealed no difference in the immuno-
stained bands in lane 1 in comparison with those of lane
2, (data not shown).
Immunocytochemistry
As previously described, application of 50 µM gluta-
mate to cerebellar granule cells induced a significant
increase in the level of tau immunoreactivity, which has
been functionally associated with neuronal death (Pizzi
et al., 1995a). In the present study we examined the
effect of repeated treatment of sabeluzole on the gluta-
mate-induced increase of tau expression in cerebellar
granule cells. In particular, immunocytochemistry for
tau proteins was carried out with Alz50, a mouse
monoclonal antibody raised against Alzheimer’s dis-
ease brain homogenates. Cells were repeatedly treated
with vehicle or 50 nM sabeluzole and challenged with
50 µM glutamate. The glutamate pulse increased tau
immunoreactivity in most of the vehicle-treated neu-
rons. Repeated treatment of cells with sabeluzole signifi-
cantly reduced the capability of glutamate to increase
Alz50 immunostaining.As shown in Figure 6, semiquan-
titative analysis of Alz50 immunoreactivity revealed a
60% decrease of gray intensity in cells repeatedly
treated with sabeluzole, compared with vehicle-treated
cells.
Neuroprotective effects of sabeluzole in human
neuroblastoma cell line SH-SY5Y
Neurotoxicity
The neuroprotective effects of sabeluzole were also
tested in the human neuroblastoma cell line SH-SY5Y,
differentiated in neuron-like cells by treatment with
retinoic acid for 3 weeks. Since these cells do not
express functional glutamate receptors, doxorubicin
was chosen as cytotoxic agent. As in cerebellar granule
cells, the neuroprotective effects of sabeluzole were
evaluated using two different experimental paradigms:
after acute treatment (i.e., 20 min before doxorubicin
treatment) or after repeated treatment (i.e., by expos-
Fig. 5. Western blot analysis with anti-tau antibody of protein
extracts from cerebellar granule cells pretreated with vehicle (lane 1)
or 50 nM sabeluzole (lane 2). The size of molecular weight markers is
indicated at left. Sabeluzole or vehicle was added to neurons on DIV 5
and DIV 8. Experiments were done on DIV 12. Data are from a
representative experiment. Similar results were obtained using pro-
tein extracts from three separate cell preparations.
Fig. 6. Glutamate-induced increase of tau immunoreactivity in rat
cerebellar granule cells pretreated with vehicle (A) or 50 nM sabelu-
zole (B). Cells were immunostained with anti-taumonoclonal antibody
Alz-50. Sabeluzole or vehicle was added to neurons on DIV 5 and DIV
8. Experiments were done on DIV 12. Columns represent the mean 6
SEM of the percentage of cells for each level of gray with A , B , C,
expressed as integrated density/area. Details in Materials and Meth-
ods.
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ing cells to the drug twice during in vitro differentia-
tion, before doxorubicin treatment). In the former case,
differentiated SH-SY5Y cells were pretreated with ve-
hicle or 50 nM sabeluzole for 20 min, and then 10 nM
doxorubicin were added to the dishes and left for an
additional 24 h. As shown in Figure 7, sabeluzole
treatment was unable to prevent the neurotoxic effects
induced by doxorubicin.
To test the effect of repeated sabeluzole treatment,
cells were exposed to vehicle or 50 nM sabeluzole
during their differentiation, specifically on DIV 14 and
DIV 18. OnDIV 21, the cultures were incubated with 10
µM doxorubicin for 24 h and then tested for viability. As
shown in Figure 7, sabeluzole was able to significantly
prevent the neurotoxicity induced by doxorubicin. In
particular, repeated sabeluzole treatment inhibited dox-
orubicin-induced LDH release by 30%.
Tau expression
PCR analysis was performed to evaluate tau mRNA
content in undifferentiated and differentiated SH-
SY5Y cells.Agarose gel electrophoresis of PCR products
revealed two distinct cDNA bands. This pattern was
similar to that described for cerebellar granule cells: a
long and a short isoform, respectively defined as adult
and fetal tau mRNA isoforms. Undifferentiated SY5Y
cells expressed predominantly the fetal tau isoform
(Fig. 8, lane 3). After 3 weeks of retinoic acid treatment,
two mRNA species, respectively encoding the fetal and
the mature tau isoforms, were detected. In differenti-
ated cells, the fetal tau mRNA isoform appeared to be
more abundant than the adult one (Fig. 8, lane 2). Two
additional weeks of retinoic acid treatment did not
modify this pattern (data not shown). Measurement of
tau mRNA levels in differentiated SH-SY5Y cells that
were pretreated with 50 nM sabeluzole on DIV 14 and
DIV 18 gave PCR products similar in size and quantity
to those found in control cells (Fig. 8, lane 1).
Immunocytochemistry
SH-SY5Y cells were incubated with 10 nM doxorubi-
cin for 2 h, and then immunocytochemical analysis was
performed with Alz50 antibody. Doxorubicin induced a
significant increase of tau immunoreactivity, similar to
that induced by glutamate in cerebellar granule cells.
Fig. 7. Doxorubicin-induced LDH release in human neuroblastoma cell line SH-SY5Y pretreated with
vehicle (open bars), 50 nM sabeluzole in acute (shaded bars), or 50 nM sabeluzole on DIV 14 and 18 (solid
bars). LDH release was measured 24 h after 10 nM doxorubicin treatment. Data (mean 6 SEM of five or
six determinations) are from a representative experiment repeated with similar results in at least three
preparations of cells. Details in Materials and Methods.
Fig. 8. PCR analysis of taumRNAisoforms from human neuroblas-
toma SH-SY5Y cells. Lane 1, retinoic acid-differentiated cells pre-
treated with vehicle on DIV 14 and DIV 18. Lane 2, retinoic
acid-differentiated cells pretreated with 50 nM sabeluzole on DIV 14
and DIV 18. Lane 3, undifferentiated cells. Arrows indicate PCR
products originating from the fetal and adult tau mRNA isoforms.
Data are from a representative experiment. Details in Materials and
Methods.
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Fifty nM sabeluzole, added to the culture on DIV 14 and
DIV 18 during differentation, were able to prevent the
glutamate-induced increase of tau expression.As shown
in Figure 9, semiquantitative analysis ofAlz50 immuno-
reactivity revealed a 65% decrease in gray intensity in
cells repeatedly treated with sabeluzole, compared with
vehicle-treated cells.
DISCUSSION
The present data show that when either primary
neurons from rat brain or differentiated human neuro-
blastoma cell lines are exposed to low concentrations of
sabeluzole, they become more resistant to neurotoxic-
ity. Apparently, these cells are primed by two pulses of
sabeluzole to develop long-lasting modification in those
intracellular pathways, that are intrinsically designed
to organize a positive functional response to an environ-
mental injury.
In particular, treatment of primary cultures of cerebel-
lar granule cells during in vitro development with
nanomolar concentrations of sabeluzole results in ma-
ture cells that are resistant to the excitotoxicity in-
duced by glutamate. There are several observations
supporting the hypothesis that sabeluzole may not act
at glutamate receptor level: 1) sabeluzole was inactive
in preventing glutamate-induced neural death after
acute treatment, 2) at neuroprotective concentrations,
it did not alter the capability of glutamate to increase
intracellular calcium levels, and 3) it elicited its neuro-
protective activity in an experimental paradigm in
which neurotoxicity was induced by a drug, doxorubi-
cin, which does not interact with plasma membrane
receptors (see below).
The neuroprotective properties elicited by sabeluzole
were more evident at a higher concentration of gluta-
mate. Moreover, at maximally effective concentrations,
the degree of neuroprotection induced by sabeluzole
never reached 100%. Taken together, these observa-
tions suggest that glutamate-induced neurodegenera-
tion may either involve distinct pathways leading to
cell death or unravel different sets of neurons with
different thresholds to neurotoxic stimuli. Whatever
the case, our data suggest that sabeluzole is either
active in preventing a specific intracellular pathway
leading to cell death, or else neuroprotective only on a
subpopulation of neurons.
Functionally, sabeluzole treatment prevented the
glutamate-elicited increase of tau immunoreactivity
detected with Alz50 antibody 2 h after the neurotoxic
pulse. The involvement of tau in the mechanism of
action of sabeluzole has been indirectly suggested by
previous studies showing that tau protein epitopes
recognized by the Alz50 antibody induced by hyper-
stimulation of various protein kinases in neuroblas-
toma cells and in hippocampal neurons were inhibited
by sabeluzole (Geerts et al., 1993). On this basis, we
were interested in investigating if the addition of
sabeluzole at specific stages of granule cell in vitro
development might change the pattern of expression of
tau protein. First, we tested the possibility that sabelu-
zole treatment may modify tau mRNA levels during
granule cell maturation. We found that, in the first day
of culturing, granule cells expressed predominantly the
tau mRNA short isoform, on DIV 6 they expressed both
the short and the long isoforms, and on DIV 12 the cells
almost exclusively expressed the long tau mRNA iso-
form. The ratio of the two tau mRNA isoforms could
thus be used as a marker of neural maturation. Sabelu-
zole treatment apparently did not modify the basal
pattern of expression of tau proteins during develop-
ment, as shown by measurement of the mRNA levels of
the two different tau isoforms. Moreover, Western blot
analysis with a phosphate-independent polyclonal tau
Fig. 9. Doxorubicin-induced increase of tau immunoreactivity in
differentiated human neuroblastoma SH-SY5Y cells pretreated with
vehicle (A) or 50 nM sabeluzole (B). Cells were immunostained with
anti-tau monoclonal antibody Alz50. Sabeluzole or vehicle was added
to cells on DIV 14 and DIV 18. Experiments were done on DIV 21.
Columns represent the mean 6 SEM of the percentage of cells for each
level of gray with A , B , C, expressed as integrated density/area.
Details in Materials and Methods.
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antibody showed that treatment with sabeluzole during
cell maturation did not alter the pattern of tau expres-
sion in terms of protein levels and posttranslational
modifications.
We then performed a second set of experiments using
a different experimental model, the human neuroblas-
toma cell line SH-SY5Y, differentiated in neuron-like
cells after treatment with retinoic acid. Since these
cells do not express functional glutamate receptors,
doxorubicin was used as an experimental tool to induce
neurotoxicity. Doxorubicin is an anthracycline antibi-
otic, a cytotoxic drug that causes DNA damage (Argas-
inski et al., 1989; Tewey et al., 1994). We found that
doxorubicin was toxic to differentiated SH-SY5Y cells.
Interestingly, this drug, like glutamate, increased tau
immunoreactivity 2 h after treatment. Both doxorubicin-
induced cell death and neurotoxicity were prevented by
exposing the cells to sabeluzole during differentiation.
The mechanism(s) responsible for the sabeluzole
neuroprotective priming effect is still unclear. The drug
was indeed able to prevent neurotoxicity induced by
agents acting on different mechanisms and/or at differ-
ent cellular levels. Sabeluzole did not modify the pro-
gram of development dictating the differential expres-
sion of the various tau isoforms, in terms of both mRNA
and protein levels. However, sabeluzole was able to
prevent the increase in tau immunoreactivity induced
by the two neurotoxic agents glutamate and doxorubi-
cin.
In summary, we found that increased tau expression
is a common response of different types of cells to
neurotoxic agents, and that neuroprotection is function-
ally associated with the prevention of the injury-
mediated increase of tau expression.
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